Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2 study of paclitaxel-based intraperitoneal chemotherapy with or without HIPEC for gastric cancer with peritoneal metastasis
ChiCTR2200056545Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and tegafur in gastric cancer (GC) (3 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoints: Progression-free survival and Overall survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
paclitaxeltegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2200056545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056545.